ID

36462

Descripción

Safety and Efficacy of BMMNC in Multiple Sclerosis (MS); ODM derived from: https://clinicaltrials.gov/show/NCT01883661

Link

https://clinicaltrials.gov/show/NCT01883661

Palabras clave

Versiones (1)
  1. 16/5/19 16/5/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

16 de mayo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Sclerosis NCT01883661

Inglés

Eligibility Multiple Sclerosis NCT01883661

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed diagnosis of ms, aged 18 - 65 years. duration of disease: >5 years signed, written informed consent willing and able to comply with study visits according to protocol for the full study period
Descripción

Multiple Sclerosis Disease length | Age | Informed Consent | Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0026769
UMLS CUI [1,2]
C0872146
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0021430
UMLS CUI [4]
C0525058
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results
Descripción

Heart failure | Kidney Failure | Liver Failure | Disease At risk Patient | Disease Interferes with Interpretation Research results

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018801
UMLS CUI [2]
C0035078
UMLS CUI [3]
C0085605
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C1444641
UMLS CUI [4,3]
C0030705
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0459471
UMLS CUI [5,4]
C0683954
patient with any active or chronic infection
Descripción

Communicable Disease | Chronic infectious disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0151317
no life-threatening organ dysfunction.
Descripción

Organ dysfunction Life Threatening

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0349410
UMLS CUI [1,2]
C2826244
pregnancy or risk of pregnancy.
Descripción

Pregnancy | At risk Pregnancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2,1]
C1444641
UMLS CUI [2,2]
C0032961
patients who are seropositive for hiv1, hiv2, hepatitis b surface antigen, and hepatitis c
Descripción

HIV-1 Seropositive | HIV-2 Seropositive | Hepatitis B Surface Antigens Seropositive | Hepatitis C Seropositive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019704
UMLS CUI [1,2]
C0521143
UMLS CUI [2,1]
C0019707
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019168
UMLS CUI [3,2]
C0521143
UMLS CUI [4,1]
C0019196
UMLS CUI [4,2]
C0521143
patients unable to give written informed consent in accordance with research ethics board guidelines
Descripción

Informed Consent Unable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
Descripción

Therapeutic immunosuppression | natalizumab | fingolimod

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021079
UMLS CUI [2]
C1172734
UMLS CUI [3]
C1699926
treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization
Descripción

Interferon-beta | glatiramer acetate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0015980
UMLS CUI [2]
C0289884
treatment with corticosteroids within the 30 days prior to randomization
Descripción

Adrenal Cortex Hormones

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001617
current treatment with an investigational therapy
Descripción

Therapy, Investigational

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0949266
Volver a la parte superior de la página

Similar models

Eligibility Multiple Sclerosis NCT01883661

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis Disease length | Age | Informed Consent | Protocol Compliance
Item
confirmed diagnosis of ms, aged 18 - 65 years. duration of disease: >5 years signed, written informed consent willing and able to comply with study visits according to protocol for the full study period
boolean
C0026769 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0021430 (UMLS CUI [3])
C0525058 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Heart failure | Kidney Failure | Liver Failure | Disease At risk Patient | Disease Interferes with Interpretation Research results
Item
patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results
boolean
C0018801 (UMLS CUI [1])
C0035078 (UMLS CUI [2])
C0085605 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C1444641 (UMLS CUI [4,2])
C0030705 (UMLS CUI [4,3])
C0012634 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0459471 (UMLS CUI [5,3])
C0683954 (UMLS CUI [5,4])
Communicable Disease | Chronic infectious disease
Item
patient with any active or chronic infection
boolean
C0009450 (UMLS CUI [1])
C0151317 (UMLS CUI [2])
Organ dysfunction Life Threatening
Item
no life-threatening organ dysfunction.
boolean
C0349410 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
Pregnancy | At risk Pregnancy
Item
pregnancy or risk of pregnancy.
boolean
C0032961 (UMLS CUI [1])
C1444641 (UMLS CUI [2,1])
C0032961 (UMLS CUI [2,2])
HIV-1 Seropositive | HIV-2 Seropositive | Hepatitis B Surface Antigens Seropositive | Hepatitis C Seropositive
Item
patients who are seropositive for hiv1, hiv2, hepatitis b surface antigen, and hepatitis c
boolean
C0019704 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0019707 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019168 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0019196 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
Informed Consent Unable
Item
patients unable to give written informed consent in accordance with research ethics board guidelines
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Therapeutic immunosuppression | natalizumab | fingolimod
Item
treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
boolean
C0021079 (UMLS CUI [1])
C1172734 (UMLS CUI [2])
C1699926 (UMLS CUI [3])
Interferon-beta | glatiramer acetate
Item
treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization
boolean
C0015980 (UMLS CUI [1])
C0289884 (UMLS CUI [2])
Adrenal Cortex Hormones
Item
treatment with corticosteroids within the 30 days prior to randomization
boolean
C0001617 (UMLS CUI [1])
Therapy, Investigational
Item
current treatment with an investigational therapy
boolean
C0949266 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial